Progressive Supranuclear Palsy Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy
NORTH CHICAGO, Ill., Jan. 25, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an investigational anti-tau antibody, in patients with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 25, 2017 Category: Pharmaceuticals Source Type: clinical trials
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy Interventions: Drug: ABBV-8E12; Drug: Placebo Sponsor: AbbVie Not yet recruiting - verified December 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2016 Category: Research Source Type: clinical trials
